Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases.
Over a 10-year period (1982-1991); a total of 150 patients divided into two groups with varying degrees of oral submucous fibrosis (OSF) were treated by either medical or surgical therapies. Medical treatment involved (a) conservative oral administration of vitamin B-complex, buflomedial hydrochloride and topical triamcinolone acetonide 0.1%, or (b) conventional submucosal injections of a combination of dexamethasone and hyaluronidase, or (c) a combination of both (a) and (b). The surgical group was treated by the excision of fibrotic tissues and covering the defect with split-thickness skin, fresh human amnion, or buccal fat pad (BFP) grafts. Treatment was chosen according to the stage of clinical progression to gain maximal interincisal distance (ID). The cases were followed up by monthly examinations for at least two years, or when possible even longer. A combination of (a) and (b) medical treatment was satisfactory in cases of mild impairment (ID > 20 mm) but in the long term it led to symptomatic relief only. Surgical therapy, on the other hand, when accepted by the patients, led to a significant improvement of trismus in cases of severe limitation (ID < 20 mm). Following this strategy, an additional ID increase was observed in all patients. BFP grafting was particularly successful in diminishing scarring after two years as compared with the other two grafts. Together with a cessation of the betel quid chewing habit before and after therapy, these treatment regimens combined with daily mouth opening exercises were found to be necessary to manage OSF cases in early and advanced stages of progression.
Lai
D R
DR
School of Dentistry, Kaohsiung Medical College, Taiwan, Republic of China.
Chen
H R
HR
Lin
L M
LM
Huang
Y L
YL
Tsai
C C
CC
D000273:Adipose Tissue / Q000637:transplantation; D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000650:Amnion; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002921:Cicatrix / Q000517:prevention & control; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use; D007267:Injections; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D009914:Oral Submucous Fibrosis / Q000188:drug therapy* / Q000601:surgery*; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use; D016038:Skin Transplantation; D013524:Surgical Flaps; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use; D014313:Trismus / Q000517:prevention & control; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D011759:Pyrrolidines; D014665:Vasodilator Agents; D014803:Vitamin B Complex; D003907:Dexamethasone; D006821:Hyaluronoglucosaminidase; D014222:Triamcinolone Acetonide; C010651:buflomedil